Zevra Therapeutics Posts Strong Q2 2026 Revenue Growth on MIPLYFFA Momentum — Zevra Therapeutics, Inc.

Event summary

$39.7 million net revenue in Q2 2026, up 53% YoY, driven by MIPLYFFA sales
14 new MIPLYFFA prescriptions for Niemann-Pick disease type C in the U.S., totaling 184 since launch
$260.2 million cash position as of June 30, 2026, supporting strategic priorities
Phase 3 DiSCOVER trial for celiprolol enrolls 66 patients with 3 confirmed events

The big picture

Zevra Therapeutics' Q2 2026 results highlight its strong commercial execution with MIPLYFFA, a therapy for Niemann-Pick disease type C. The company's focus on expanding access to arimoclomol in Europe and advancing its pipeline, particularly the Phase 3 DiSCOVER trial for celiprolol, positions it within the competitive landscape of rare disease treatments. With a robust cash position, Zevra is well-equipped to execute its strategic priorities independently from capital markets.

What we're watching

Regulatory Progress: Whether the EMA's re-examination of MIPLYFFA's Marketing Authorisation Application will lead to approval in Europe, expanding market access.
Pipeline Momentum: The pace at which Zevra advances its Phase 3 DiSCOVER trial for celiprolol and engages with the FDA on potential acceleration pathways.
Commercial Execution: How Zevra sustains MIPLYFFA's prescription growth in the U.S. while maintaining stable market access at 69% of covered lives.